keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MOG (35-55), human, a constituent of central nervous system myelin, is distinguishable from mMOG (35-55) due to a proline-to-serine substitution at position 42. It possesses immunogenic properties and is partially cross-reactive with mMOG35–55. However, MOG (35-55), human does not induce encephalitogenic effects, and only elicits minimal clinical signs of EAE (experimental autoimmune encephalomyelitis) in comparison to the rodent peptide.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | MOG (35-55), human, a constituent of central nervous system myelin, is distinguishable from mMOG (35-55) due to a proline-to-serine substitution at position 42. It possesses immunogenic properties and is partially cross-reactive with mMOG35–55. However, MOG (35-55), human does not induce encephalitogenic effects, and only elicits minimal clinical signs of EAE (experimental autoimmune encephalomyelitis) in comparison to the rodent peptide. |
Molecular Weight | 2592.03 |
Formula | C120H179N35O28S |
CAS No. | 163158-19-8 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MOG (35-55), human 163158-19-8 MOG (35 55), human MOG , human MOG (3555), human inhibitor inhibit